Cas-CLOVER: Advanced Gene Editing To Improve Bioprocessing in CHO Cells
Contact us to learn more about our gene editing technology.
If you have experienced unwanted off-target mutations or confusing licensing and freedom to operate issues when using gene editing tools like CRISPR, you are not alone.
Demeetra is here to help.
Our Cas-CLOVER gene editing technology has undetectable off-target activity and stand alone patent protection for licensing simplicity and clarity in freedom to operate.
Evaluate Cas-CLOVER in-house or collaborate with us to execute your proof of concept services. Then, partner with us for accessible commercial and research licenses for the area of therapeutic bioprocessing for a more rewarding gene editing experience.
Contact us to learn more.
Cas-CLOVER Enhances Therapeutic Bioprocessing
Advanced gene editing can treat many different types of disease ranging from cancer and autoimmune diseases to neurologic disorders.
Cas-CLOVER has the potential to revolutionize the world of therapeutics by making precise, intentional and beneficial changes in the genetic material resulting in permanent changes instead of only treating symptoms.
Validated In CHO Cells
The Cas-CLOVER system has been validated in Chinese hamster ovary (CHO) cells for bioprocessing.
When the endogenous glutamine synthetase (GS) gene is knocked out in CHO cells, a six-fold increase in high-producing cell lines is achieved. Combining newer gene editing tools like Cas-CLOVER that have specific targeting capabilities with the robust CHO expression systems has significantly impacted bulk cell culture productivity. There’s an increased rate of high- producing cells resulting in improved efficiency.
Shown here are indel frequencies of 18% and 43% at the CHO GS locus for one and two rounds of targeting, respectively. These on-target frequencies in CHO cells are higher than reported for ZFN and comparable to those of CRISPR/Cas9.
Learn more by downloading our datasheet.
What’s Unique About The Cas-CLOVER Gene Editing System?
As opposed to the use of a single guide RNA (gRNA) for sequence-specific gene editing, the Cas-CLOVER system utilizes a dual gRNA in addition to the Clo51 nuclease activity that requires dimerization of subunits associated with each guide RNA.
This allows for more stringent DNA cleavage. Using two gRNA makes the Cas-CLOVER gene editing system highly restricted and only functional when the paired gRNAs coexist.
Freedom To Operate Is Clear With Cas-CLOVER
The lack of clear commercial freedom to operate and use of intellectual property (IP) has limited the commercial use of current gene editing tools. It is our mission to make technology easily accessible to all scientists and researchers within the pharmaceutical bioprocessing, industrial biotechnology, and agriculture industries.
Due to the distinct science involved, Cas-CLOVER is covered under a set of patents separate from other technologies. Cas-CLOVER is exclusively licensed and sub-licensable by Demeetra.
Watch Our Video
Enhance your gene editing research or commercial interests with Cas-CLOVER. Watch to see the unique ways Cas-Clover can work for you
Shop Cas-CLOVER Gene Editing Reagents Today
Buy Cas-CLOVER reagents for use in mammalian, plant, and yeast gene editing by visiting our easy-to-use shop page. After purchasing the vials and signing a simple royalty-free MTA form, we’ll send you our basic use protocol, which includes maps, sequences, instructions on design and production of the gRNAs.
Scientists Trust Our Gene Editing Technology
We are very happy with the efficiency of the targeted mutations we are getting with Cas-CLOVER in mammalian cells. It is impressive that although Cas-CLOVER requires dimerization it still has very high efficiency similar to CRISPR/Cas9. The one aspect of Cas-CLOVER that stood out for us was its ease of use. We have been working with CRISPR/Cas9 for many year now and Cas-CLOVER just fit in very nicely with our existing workflow for gene-editing with Cas9 or Cas9 nickase.
Tseten Jamling, PhD.
VP, R&D & Gene Editing
Hera BioLabs
Cas-CLOVER’s ability to edit resting primary T cells with efficiency and fidelity allows us to generate fully allogeneic CAR-T products rich in TSCM cells.
Maximilian Richter, PhD.
Senior Scientist,
Immuno-Oncology
Poseida Therapeutics
We Enable Scientists To Obtain More With Less Inconvenience
Contact us to learn more about our gene editing technology.
DEMEETRA AGBIO, INC.
2277 THUNDERSTICK DR. #500 LEXINGTON, KY 40505 US
COPYRIGHT © 2020 DEMEETRA AGBIO, INC. - ALL RIGHTS RESERVED.